Clinical trials: NTRK Gene Fusion
Advanced Solid Tumor
Study of FCN-011 in Patients With Advanced Solid Tumor（Phase I）and NTRK Fusion Positive Advanced Solid Tumor （Phase II）
A multicenter, open, single-arm phase I dose exploration and phase II extended study was conducted to evaluate the safety, tolerability, pharmacokinetic characteristics, and primary antitumor activity of FCN-011 in patients with…
- Trial name
- NCT04687423
- Testing
- FCN-011
- Where
- China
- Volunteers
- 82 people
- Sponsor
- Fochon Pharmaceuticals, Ltd.